Research programme: tuberculosis therapeutics - Shreya Life Sciences
Latest Information Update: 26 Jul 2016
At a glance
- Originator Shreya Life Sciences
- Developer National Institute of Oceanography; Shreya Life Sciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 25 Jul 2016 Preclinical trials in Tuberculosis in India (unspecified route)